Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
Pfizer Inc. (NYSE:PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer.
Pfizer announced that its Braftovi regimen demonstrated a statistically significant improvement in progression-free survival (PFS) for patients with a specific mutation in metastatic colorectal cancer.
Colorectal Cancer Data
Pfizer released topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and Folfiri (fluorouracil, leucovorin, and irinotecan) for previously untreated metastatic colorectal cancer with a BRAF V600E mutation.
This follows the pivotal BREAKWATER trial, where the regimen showed promising results compared to traditional treatments.
In January, Pfizer shared data from Cohort 3 of the BREAKWATER trial, wherein the Braftovi combination regimen cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) compared to patients receiving standard-of-care treatment FOLFIRI with or without bevacizumab (64.4% vs 39.2%, odds ratio =2.76, p=0.001).
Overall, the Phase 3 BREAKWATER trial demonstrated a clinically meaningful and statistically significant improvement in confirmed ORR compared to patients receiving chemotherapy with or without bevacizumab (60.9% vs. 40.0%).
Technical Analysis
Currently, Pfizer is trading 3.5% below its 20-day simple moving average (SMA) and 5.2% below its 100-day SMA, indicating some short-term weakness. Shares have increased 7.90% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum for Pfizer at this time.
- Key Resistance: $27.50
- Key Support: $24.50
Analyst Consensus & Recent Actions
The stock carries a Hold Rating with an average price target of $29.67. Recent analyst moves include:
- Cantor Fitzgerald: Neutral (Maintains Target to $27)
- Cantor Fitzgerald: Neutral (Raises Target to $27)
- UBS: Neutral (Target $25)
Top ETF Exposure
- First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL): 5.87% Weight
- Invesco Pharmaceuticals ETF (NYSE:PJP): 5.01% Weight
- Franklin US Dividend Booster Index ETF (NYSE:XUDV): 4.90% Weight
PFE Price Action: Pfizer shares were up 0.63% at $27.75 at the time of publication on Tuesday. The stock is trading near its 52-week high of $27.94.
Photo by ShU studio via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Crypto prices
More
